Biotech financing and corporate shifts characterize the current market landscape. Hatteras Venture Partners closed over $200 million across two life sciences funds aimed at early-stage investments. Compass Therapeutics raised $120 million to support drug development. Conversely, Generation Bio laid off 90% of its staff due to funding constraints, while Oric cut 20% of employees to focus on clinical-stage cancer programs. Additionally, US biopharma IPO activity slowed, marking a six-month drought. Overall, investment and workforce dynamics reflect ongoing recalibrations in the sector amid economic pressures.